COLLEGIUM PHARMACEUTICAL, INC ·
COLL 8-K 2026-11-05
COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K dated 2026-11-05 — accession 0001628280-26-070585.
COLLEGIUM PHARMACEUTICAL, INC (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
COLL sales +3.0% YoY
This 8-K covers: Results of operations (Item 2.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported COLL revenue for 2026-06-30 was $199.9M. Net income was -$15.1M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. COLL currently screens at market cap $1.12B.
Not investment advice. The COLL SEC hub lists recent forms. The stock page is the research view.
- YoY
- +3.0%
- Guidance
- full-year 2026 financial guidance and remain committed to deploying capital in a disciplined manner, including executing on busin
Why it matters
- full-year 2026 financial guidance and remain committed to deploying capital in a disciplined manner, including executing on busin
- We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% o…